|
KMID : 1141720170050020003
|
|
폐쇄성폐질환
2017 Volume.5 No. 2 p.3 ~ p.3
|
|
|
In What Patients Should I Use Fixed LABA/LAMA Combination in COPD?
|
|
Um Soo-Jung
|
|
|
Abstract
|
|
|
|
Long-acting β-agonist/long acting muscarinic antagonist (LABA/LAMA) combinations are associated with a greater improvement in lung function, St. George’s Respiratory Questionnaire score, transitional dyspnea index and lesser exacerbations than monotherapies. In addition, there are no statistically significant differences between LABA/LAMA combinations and monotherapies in terms of safety outcomes. LABA/LAMA combinations are more effective than inhaled corticosteroid/LABA in preventing exacerbations in COPD patients with severe air flow limitation and previous history of exacerbations. Therefore, LABA/LAMA combinations should be considered first for patients with severe symptom, deteriorated quality of life and frequent exacerbations.
|
|
|
KEYWORD
|
|
|
Pulmonary disease, Chronic obstructive, Long-acting β2-agonists, Long-acting muscarinic antagonist, Fixed dose combination
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|